clinical trial – Page 222 – Communicable Diseases Research

Immunologic Effects of Vitamin D on Human Health and Disease

Review

Published on 2020-07-152022-10-30
Journal: Nutrients [Category] Coronavirus, SARS,

Could the Induction of Trained Immunity by β-Glucan Serve as a Defense Against COVID-19?

Immunology

Published on 2020-07-142022-11-01
Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS,

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study

Pharmacology

Published on 2020-07-142022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] acute respiratory syndrome adverse event adverse events Analysis Antiviral antiviral therapy Antiviral treatment baseline calculated clinical clinical trial Combination comparable conducted coronavirus coronavirus disease COVID-19 COVID-19 patient difference Effectiveness effectiveness and safety enrolled Follow-up group IFN-α incidence include intention-to-treat interferon-alpha Interferon-α laboratory characteristics Lopinavir/ritonavir median interval Mild Mild to moderate COVID-19 Moderate COVID-19 Mortality negativity no significant difference nucleic acid Observed outcome pandemic Patient patients with SARS-CoV-2 proportion Prospective Prospective clinical trial Randomized regimen Registration Result ribavirin SARS-CoV-2 SARS-CoV-2 nucleic acid severe cases significant increase significantly higher single-center Spread statistically study period the median three groups
[DOI] 10.3389/fphar.2020.01071 PMC 바로가기 [Article Type] Pharmacology

A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-07-132022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 24 hour 48 hour Activation acute lung injury acute pneumonia acute respiratory distress syndrome Administered Adult age all-cause mortality Amendment antibodies antibody Antibody test anticipated antiviral therapy approval ARDS assessment assigned baseline Biomarker Blood cardiac disease Care change class Clinical improvement clinical study clinical trial complement Complement inhibitor component Computed tomography concealed Concentration conducted Confirmed Controlled coronary syndrome COVID-19 criteria current Day diagnosis of SARS-CoV-2 dialysis discharge dissemination dose Duration Efficacy element eligibility Endotracheal intubation EU Clinical Trial EudraCT evaluate the effect expected failure female patient Final fraction France Germany greater half-live hospital Hospitalization humanized Hypercoagulable state Immunoglobulin Infection Inflammatory inhibitor initiated intensive care Intubated intubation invasive Invasive mechanical ventilation investigator IVIG Japan Lung injury mechanical ventilation medication monoclonal multicenter Neisseria meningitidis Non-invasive number objective Open-label original outcome oxygen participant Patient patients randomized patients with COVID-19 Period peripheral capillary phase Placebo Pneumonia polymerase chain positive airway pressure presenting progression protocol randomised randomised controlled trial randomization randomization list Randomized randomized controlled study Randomly Ravulizumab receive recruitment registry Remdesivir renal respiratory respiratory distress Respiratory distress syndrome routine clinical care Safety screened Screening secondary Serious Adverse Events serum severe acute respiratory distress syndrome coronavirus 2 Severe acute respiratory syndrome severe COVID-19 severe pneumonia SOFA Spain SpO2 Sponsor stratified Study protocol supportive care survival The United States therapy time Treatment treatment-emergent adverse event Ultomiris United Kingdom ventricular Viral website with COVID-19 X-ray
[DOI] 10.1186/s13063-020-04548-z PMC 바로가기 [Article Type] Letter

Lactoferrin as Protective Natural Barrier of Respiratory and Intestinal Mucosa against Coronavirus Infection and Inflammation

Review

Published on 2020-07-112022-10-29
Journal: International Journal of Molecular Sciences [Category] COVID-19, SARS,

The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19

Letter to the Editor

Published on 2020-07-112022-10-28
Journal: Respiratory Research [Category] COVID-19,

[키워드] Bacillus BCG clinical trial conducted country COVID-19 Evidence limitation morbidity and mortality protective effect suggested vaccination Vaccine
[DOI] 10.1186/s12931-020-01439-4 PMC 바로가기 [Article Type] Letter to the Editor

Efficacy of acupuncture and moxibustion in adjuvant treatment of patients with novel coronavirus disease 2019 (COVID-19) A protocol for systematic review and meta analysis

3800

Published on 2020-07-102022-10-30
Journal: Medicine [Category] COVID-19, SARS,

Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19

Review

Published on 2020-07-102022-10-04
Journal: Frontiers in Public Health [Category] MERS, 신약개발,

Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial

Letter

Published on 2020-07-092022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 absence Admission allergy alteration Antibody test anticipated Antigen approved assigned blinded breast-feeding Burgos Cancer chronic liver disease cirrhosis clearance clinical clinical symptom clinical trial Complete Corticosteroid Course COVID-19 COVID19 creatinine criteria delirium Department Desaturation Deterioration diabete Diagnosis dissemination drug Dyspnea Early pulmonary early stage Effectiveness element Emergency EudraCT evaluate exclusion for inclusion glucocorticoid greater group heart hidden history HIV infection hospital Hospital admission Hospital stay Hydroxychloroquine hypertension ICU admission Immunosuppression immunosuppressive include Inclusion intention-to-treat basis interactions Intervention local Ethics Committee lung lung involvement meet mild pneumonia modify number objective observation Occurrence Other other diseases outcome Outpatient outpatients Paracetamol parallel group participant Participation Patient patients’ medical records PCR per protocol performed physician Pneumonia power of 80% Prednisone professionals protocol pulmonary involvement QT prolongation radiological random randomised randomised controlled trial Randomized receive recruitment reduce reflected Registered renal responsible risk Sample size SARS-COV-2 infection sealed secondary sequence Spain Spanish status steroid Steroids stratified Stratified randomization study drug study inclusion subject Symptom the patient Treatment Trial verbal website women X-ray
[DOI] 10.1186/s13063-020-04575-w PMC 바로가기 [Article Type] Letter

The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world

Review Article

Published on 2020-07-082022-10-30
Journal: Immunology [Category] COVID-19,